Table 2.
Characteristics and outcomes of the five patients in Blinatumomab salvage therapy.
| Number | IL-6 (pg/mL) | CD3+ (%) | CD3+CD8+ (%) | CD3+CD4+ (%) | Hematological toxicity Grade |
CRS Grade | ICANS Grade | Infection | Response to Blinatumomab | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Neutrophil | Haemoglobin | Platelets | |||||||||
| Pt 1 | 5.81–28.4 | 81–85 | 42–45 | 37–38 | 2 | 1 | 2 | 1 | 0 | RMP | CR MRD− |
| Pt 2 | 13.40–162.5 | 87–91 | 49–52 | 36–39 | 2 | 3 | 3 | 2 | 1 | BP | CR MRD+ |
| Pt 3 | 6.80–4.10 | 88–91 | 45–47 | 41–43 | 1 | 0 | 1 | 1 | 0 | BP, CE | CR MRD− |
| Pt 4 | 4.37–12.72 | 92–96 | 28–39 | 50–63 | 2 | 1 | 0 | 1 | 0 | – | CR MRD− |
| Pt 5 | 6.94–10.5 | 71–73 | 25–28 | 44–47 | 2 | 2 | 3 | 0 | 0 | – | PR |
CD3+: CD3+ T cells in peripheral blood; CD3+CD8+: CD3+CD8+ T cells in peripheral blood; CD3+CD4+: CD3+CD4+ T cells in peripheral blood; MRD: Minimal residual disease; RMP: Rhizopus microsporus pneumonia; BP: Bacterial pneumonia; CE: Cryptococcal encephalopathy.